r.danquah

TL2 · Turku

Contributes reviews on supplier material. Based in Turku.

Joined 24 March 2025 · last posted 4d

81 posts, newest first. Showing up to 150.

Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #109 · Analytics › Impurities & related substances · 24 Jul 2026 · 2 likes Picking up post #106: that is the part I would want checked first. Deamidation at asparagine and glutamine: adds 1 approximately. Frequently appears as a close-eluting…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #112 · Sourcing › Independent verification · 21 Jul 2026 · 7 likes Thank you for the correction. I would rather find out here than later.
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #67 · Evidence › Journal club · 15 Jul 2026 · 5 likes Post #64 is the version of this I will quote in future. One addition. The figures usually contain the finding and the text usually contains the interpretation.…
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #107 · Evidence › Journal club · 5 Jul 2026 · 0 likes Post #104 answers the question as asked. The question underneath it is different. Something worth flagging about indirect comparison: the strongest-sounding claims in…
A pooled estimate that changed when one trial was added Replied, post #17 · Evidence › Meta-analyses · 1 Jul 2026 · 0 likes Taking post #15 at face value and following it one step further. A note on scope: what I am saying about pooled estimate applies to the case in the first post and I…
Research-use-only status: what it means legally and practically Replied, post #67 · Compounds › Other compounds · 30 Jun 2026 · 0 likes For anyone finding this later: the short answer on research-use-only status is that it depends on one thing, and the rest of the thread is people identifying which thing.
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #16 · Compounds › Retatrutide · 27 Jun 2026 · 12 likes The version of glucagon receptor agonist that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
What I would want from a home test that does not exist yet — what changed since Replied, post #62 · Analytics › Home & field testing · 20 Jun 2026 · 0 likes Post #58 and I disagree about the size of the effect, not about the direction. Where home testing is genuinely valuable is as a screen before spending on independent…
Mass error in ppm: the arithmetic and the caveat — a second dataset Replied, post #10 · Analytics › Mass spectrometry · 18 Jun 2026 · 0 likes Tandem mass spectrometry: MS/MS fragments the molecular ion and uses fragment masses to confirm identity and detect modifications. A simple identity confirmation by…
Tracking a shortage from primary sources rather than rumour Replied, post #53 · Access › Shortages · 16 Jun 2026 · 17 likes Trying to state the tracking a shortage position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes…
Alcohol: what is documented and what is folklore Replied, post #55 · Practice › Interactions · 13 Jun 2026 · 4 likes What I would tell a new member reading about alcohol for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #80 · Practice › Storage & stability · 7 Jun 2026 · 1 like Building on post #79 rather than restating it. A methods point on reconstituted rather than a substantive one: if the comparison is not like for like, the difference…
Follow-up: Search filters: what is missing Replied, post #112 · Meta › Site feedback · 26 May 2026 · 28 likes Worth separating two things that post #109 runs together. My position on Search filters is current rather than settled. I have revised it once already and I expect to…
Journal club: semaglutide in MASH, and surrogate endpoints Replied, post #20 · Evidence › Journal club · 25 May 2026 · 3 likes Taking post #17 at face value and following it one step further. The reason semaglutide in MASH is hard to answer is that the obvious measurement and the relevant…
Revisiting: PCOS and metabolic overlap: what is and is not studied Replied, post #31 · Clinical › Comorbidities · 22 May 2026 · 5 likes Building on post #30 rather than restating it. PCOS and metabolic overlap is well covered in the tag pages, and the older discussions are better than the recent ones…
[2026 update] Regional warehouse stock versus direct despatch Replied, post #77 · Sourcing › Logistics · 22 May 2026 · 10 likes Regional stock shortens the exposure window more than any packing improvement and is the practical argument for it beyond speed. None of the above is medical advice and…
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #2 · Compounds › Secretagogues & GH axis · 12 May 2026 · 5 likes Quietly grateful for the plain phrasing. Not every thread gets that.
Run-in periods and the population they select Replied, post #114 · Evidence › Trials · 9 May 2026 · 13 likes Clear enough that I do not think I have a follow-up, which is unusual.
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #46 · Evidence › Preprints · 5 May 2026 · 4 likes Where a preprint's numbers are the basis of a claim being repeated here, someone should check whether the published version exists yet. That check is nearly always…
Step therapy requirements and how to satisfy them Replied, post #8 · Access › Insurance & coverage · 28 Apr 2026 · 5 likes Answering the question post #6 raises rather than the one it answers. Formulary status: the list of covered medications and the tier (how much you pay) they are on.…
Reference intervals: how they are constructed and why one in twenty flags Replied, post #84 · Clinical › Bloodwork · 21 Apr 2026 · 7 likes The most useful thing this subcategory does is help people tell an interesting result from an uninteresting one before booking an appointment about it. Marking that as…
Converting between mg/mL and units per dose, both directions — the long version Replied, post #43 · Practice › Reconstitution · 20 Apr 2026 · 4 likes Choose the concentration so that a typical dose lands on a graduation you can actually read. A dose that falls between two marks on a 1 mL barrel is a dose you will get…
The best-written scientific paper you have read Replied, post #3 · Lounge › Off topic · 11 Apr 2026 · 0 likes The most useful thing anyone has posted about best-written scientific paper in this category was a table of what had been measured and by whom. That is what I would…
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #26 · Outcomes › Progress reports · 2 Apr 2026 · 0 likes Maintenance series are the ones this subcategory needs most and receives least. The interesting questions all change once loss stops.
Adsorptive losses at low concentration, and why dilute solutions are fragile Replied, post #19 · Practice › Storage & stability · 13 Mar 2026 · 0 likes That is the distinction I keep failing to hold on to. Written down now.
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #40 · Outcomes › Body composition · 12 Mar 2026 · 6 likes Preserving lean tissue during a substantial deficit depends on protein intake and a resistance stimulus, and the evidence for both is reasonably strong.
Grapefruit: why this class is not the class that cares Replied, post #17 · Practice › Interactions · 7 Mar 2026 · 0 likes Taking post #14 at face value and following it one step further. On grapefruit, I would rather understate and be corrected upward than overstate and be quoted. That is…
Reading a preclinical wound-healing model and its relevance to a human tendon — a second… Started this topic · Compounds › Repair & healing peptides · 6 Mar 2026 · 50 likes Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable.…
The "under review" status pill and when a moderator applies it Replied, post #6 · Evidence › Preprints · 3 Mar 2026 · 0 likes On post #2 — agreed on the reasoning, with one qualification. Building anything durable on a preprint means committing to rebuild it. That is a reasonable trade for a…
Reading an interaction checker output critically Replied, post #121 · Practice › Interactions · 16 Feb 2026 · 0 likes That is clearer than the version I had in my head. Thank you.
Chain of custody for a sample you posted yourself — one year on Replied, post #4 · Sourcing › Independent verification · 12 Feb 2026 · 2 likes Post #2 and I disagree about the size of the effect, not about the direction. Cross-checking one lot with two services independently is the cleanest test available and…
[2026 update] A rising related-substance total over six months: degradation or method… Replied, post #25 · Analytics › Impurities & related substances · 12 Feb 2026 · 18 likes Practical experience of rising related-substance, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make…
Bioimpedance and hydration: why the number moves Replied, post #3 · Outcomes › Body composition · 29 Jan 2026 · 32 likes Photographs under fixed lighting and posture are a genuine record and are the hardest of these to standardise.
Search filters: what is missing Replied, post #22 · Meta › Site feedback · 29 Jan 2026 · 0 likes The arithmetic on search filters is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
Second pass at: Metformin co-administration and additive GI effects Replied, post #38 · Practice › Interactions · 24 Jan 2026 · 9 likes Picking up post #37: that is the part I would want checked first. What I want from this Metformin co-administration thread is the list of things that would need to be…
Trifluoroacetate content and its consequences Replied, post #2 · Analytics › Impurities & related substances · 20 Jan 2026 · 12 likes Fair, and the limits you put on it are the part I will remember.
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #57 · Sourcing › Red flags · 20 Jan 2026 · 0 likes Claims of pharmaceutical-grade status for research-use-only material are a labelling problem and are common enough to be worth expecting rather than reacting to.
Second pass at: How to ask a question when you cannot say why you are asking it Replied, post #50 · Start Here › How to Ask · 8 Jan 2026 · 0 likes It is fine to say you cannot explain why you are asking. Nobody will press, and the technical part of the question can usually be answered without the context. I would…
When your prescriber and the evidence disagree Replied, post #2 · Clinical › Prescriber conversations · 5 Jan 2026 · 0 likes The opening post describes the usual case. This is about the unusual one. How to ask for what you need: rather than "should I take this", frame it as "I understand the…
Documentation that appears only after payment Replied, post #105 · Sourcing › Red flags · 13 Dec 2025 · 14 likes Reading rather than answering, but this is the post I would point somebody at.
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #47 · Clinical › Special populations · 7 Dec 2025 · 0 likes Older adults were included in the trials in smaller numbers than their share of the eventual population, so precision in that subgroup is poor. I would hold that…
Reading U-100 graduations, with a conversion table Replied, post #2 · Devices › Syringes & needles · 5 Dec 2025 · 6 likes The opening post and I disagree about the size of the effect, not about the direction. What I would want before treating reading U-100 graduations as settled: the…
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #67 · Compounds › Oral incretins · 30 Nov 2025 · 29 likes Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and…
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Replied, post #6 · Compounds › Retatrutide · 29 Nov 2025 · 14 likes How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does…
[2026 update] How much of the diluent volume the powder itself displaces Replied, post #17 · Practice › Reconstitution · 23 Nov 2025 · 29 likes A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL gives 5 mg/mL, 4 mL gives roughly 2.5 mg/mL. The arithmetic is the same; the…
Second pass at: Metformin co-administration and additive GI effects Replied, post #5 · Practice › Interactions · 11 Nov 2025 · 14 likes Two questions I would want answered before drawing anything from the Metformin co-administration data above: how were the cases selected, and what happened to the ones…
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #17 · Compounds › Tirzepatide · 7 Nov 2025 · 21 likes Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the…
"Greater than or equal to 99%" as a specification rather than a result Replied, post #66 · Analytics › COA interpretation · 7 Nov 2025 · 0 likes Thank you for taking the time. That was more work than a reply usually is.
"Should I double up?" — answered once, at length, calmly Replied, post #27 · Practice › Administration · 27 Oct 2025 · 20 likes Where I part company with post #23, and it is a narrow parting. If you have to inject at a different time of day than usual, that is a much smaller perturbation than it…
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Replied, post #82 · Evidence › Journal club · 22 Oct 2025 · 3 likes Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything…
Micronutrient adequacy at low total intake — does this still hold? Replied, post #9 · Nutrition & Training › Protein & intake · 5 Oct 2025 · 0 likes Micronutrient adequacy becomes a real question at very low total intake and is much less discussed than protein. The reasoning is more useful than the number, which is…
What a purity-only report leaves out Replied, post #9 · Sourcing › Independent verification · 8 Sep 2025 · 0 likes The arithmetic in post #8 is right; the assumption feeding it is the part to check. The version of purity-only that I was taught turned out to be a teaching…
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Replied, post #61 · Evidence › Journal club · 4 Sep 2025 · 26 likes Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your…
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #100 · Evidence › Journal club · 24 Aug 2025 · 0 likes Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything…
A ten-fold dose error caught before injection — one year on Replied, post #89 · Devices › Syringes & needles · 3 Aug 2025 · 19 likes Sharps containers are a legal requirement for disposal in several jurisdictions and a sensible precaution everywhere. A rigid sealed container is the minimum.
[2026 update] Reverting an edit that had no revision note Replied, post #9 · Meta › Wiki maintenance · 30 Jul 2025 · 1 like Support the scoping edit. A number in a maintained document gets quoted without its context roughly forever, so the context has to be inside the sentence rather than in…
A field-by-field walk through a certificate of analysis Replied, post #122 · Analytics › COA interpretation · 18 Jul 2025 · 0 likes Narrowing post #120, because the general version has more than one answer. A certificate of analysis is a statement by its issuer that a defined test was performed on a…
A field-by-field walk through a certificate of analysis Replied, post #30 · Analytics › COA interpretation · 15 Jul 2025 · 5 likes I read post #28 twice before replying, because I had assumed the opposite. Practical answer on field-by-field walk through a certificate, since the theoretical one is…
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #78 · Evidence › Journal club · 12 Jul 2025 · 6 likes Clear enough that I do not think I have a follow-up, which is unusual.
Delayed gastric emptying and oral medication absorption: which drugs matter Replied, post #109 · Practice › Interactions · 1 Jun 2025 · 3 likes Answering the question post #107 raises rather than the one it answers. Delayed gastric emptying and oral has a well-known answer and a correct answer, and the…
Ipamorelin selectivity claims and where they came from Replied, post #42 · Compounds › Secretagogues & GH axis · 30 May 2025 · 26 likes Post #41 answers the question as asked. The question underneath it is different. Why this subcategory is stricter about sourcing than most: the evidence base is weaker…
Escalating every six weeks instead of four: what I observed over eight months — one year… Replied, post #30 · Practice › Dosing & titration · 28 May 2025 · 2 likes I read post #26 twice before replying, because I had assumed the opposite. An update on my earlier Escalating every six weeks instead post: the pattern held for another…
Cost per milligram, computed honestly across formats — the long version Replied, post #80 · Access › Pricing · 27 Apr 2025 · 2 likes Quietly grateful for the plain phrasing. Not every thread gets that.
Which panel is worth repeating and which is worth ignoring Replied, post #9 · Clinical › Bloodwork · 26 Apr 2025 · 10 likes Thank you — that answers what I came here to find out.
Trial registration and comparing the protocol with the paper Replied, post #2 · Evidence › Trials · 10 Apr 2025 · 29 likes I would be cautious about generalising from the trial registration example above. It is a good example. It is one example.
Second pass at: Pen dose counters: what a click does and does not guarantee Replied, post #8 · Devices › Pens & autoinjectors · 28 Mar 2025 · 0 likes That is a fair summary of where the discussion has got to.
Coming back to: Official shortage notices and what they authorise Replied, post #5 · Access › Shortages · 6 Feb 2025 · 4 likes I read post #3 twice before replying, because I had assumed the opposite. Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed…
Why mass spectrometry cannot tell you about an epimer Replied, post #36 · Analytics › Mass spectrometry · 24 Jan 2025 · 1 like Useful. I have added it to my own notes with the date on it.
Follow-up: Individual participant data versus aggregate data Replied, post #31 · Evidence › Meta-analyses · 9 Jan 2025 · 0 likes Practical note on Individual participant data versus aggregate: write down what you expect before you look. The number of times I have found what I went looking for is…
Coming back to: Preparing for an appointment: one page, three questions Replied, post #127 · Clinical › Prescriber conversations · 20 Dec 2024 · 16 likes Where I part company with post #123, and it is a narrow parting. Written summaries after an appointment are available in many systems and are worth asking for, because…
Coming back to: Grapefruit: why this class is not the class that cares Replied, post #37 · Practice › Interactions · 14 Dec 2024 · 2 likes Speaking only to Grapefruit as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the…
[2026 update] New subcategory: rationale and scope Replied, post #8 · marked as the solution · Meta › Announcements · 16 Nov 2024 · 22 likes Where the New subcategory reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Fixed versus detachable needles: the trade-offs Replied, post #5 · Devices › Syringes & needles · 15 Nov 2024 · 0 likes Adding thanks rather than a view. I do not have a view worth the space.
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #5 · Compounds › Repair & healing peptides · 6 Nov 2024 · 22 likes Taking post #2 at face value and following it one step further. What I can speak to on reading a preclinical wound-healing model is narrow, so I will keep it narrow…
Second pass at: Reimbursement variation across member states Replied, post #24 · Regional › European Union · 26 Oct 2024 · 2 likes Post #22 and I disagree about the size of the effect, not about the direction. Italy: AIFA controls reimbursement through a note system. Weight-management indications…
Coming back to: Research-use-only labelling: what it means and what it does not Started this topic · Sourcing › Regulatory · 2 Oct 2024 · 18 likes Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. A labelling question, and I would…
Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #57 · Compounds › Retatrutide · 24 Sep 2024 · 0 likes Post #53 put the caveat in the right place and I want to underline it. My experience of hepatic effects of glucagon receptor contradicts the reply above. I am posting…
Blind submission and why it changes minds Replied, post #45 · Sourcing › Independent verification · 26 Aug 2024 · 25 likes Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want.
Promotion criteria, and the one that stops most nominations Replied, post #23 · Documentation › Doc review · 23 Jul 2024 · 4 likes A note on scope: what I am saying about promotion criteria applies to the case in the first post and I would not extend it further without checking.
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #138 · Practice › Dosing & titration · 10 Jul 2024 · 1 like Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a…
Assessing a warm arrival: the decision process — one year on Replied, post #23 · Sourcing › Logistics · 29 May 2024 · 24 likes Answering the question post #21 raises rather than the one it answers. The same route behaves differently in different months. A single good or bad experience is one…